BioCryst Pharmaceuticals (BCRX) officer reports 8,181 shares for taxes

Rhea-AI Filing Summary

BioCryst Pharmaceuticals reported an insider equity transaction by an officer serving as President and CCO. On 12/12/2025, 8,181 shares of common stock were withheld by the company at $7.57 per share to cover required tax withholding tied to the vesting of previously granted restricted stock units.

The explanation clarifies that this withholding is for tax purposes and does not represent a sale by the officer. Following this transaction, the officer directly beneficially owns 418,827 shares of BioCryst Pharmaceuticals common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gayer Charles K

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CCO

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		F		8,181(1)	D	$7.57	418,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

	/s/ Alane P. Barnes, by power of attorney	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCryst Pharmaceuticals (BCRX) report?

BioCryst Pharmaceuticals reported that an officer serving as President and CCO had shares of common stock withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units.

How many BioCryst (BCRX) shares were withheld and at what price?

The company withheld 8,181 shares of BioCryst Pharmaceuticals common stock at a price of $7.57 per share to cover tax withholding tied to restricted stock unit vesting.

When did the BioCryst Pharmaceuticals (BCRX) insider transaction occur?

The insider equity transaction took place on 12/12/2025, which is listed as both the transaction date and the date of earliest transaction.

How many BioCryst Pharmaceuticals (BCRX) shares does the officer own after the transaction?

After the tax withholding transaction, the officer directly beneficially owns 418,827 shares of BioCryst Pharmaceuticals common stock.

Does the reported BioCryst (BCRX) transaction represent a sale of shares by the officer?

No. The explanation states that the 8,181 shares represent stock withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of restricted stock units, and that this does not represent a sale by the reporting person.

What type of equity award is linked to the BioCryst (BCRX) withholding transaction?

The withholding relates to the vesting of previously granted restricted stock units, and the shares were retained by the company to cover the associated tax obligations.